Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD
Papers referenced in the video:
Life-Span Extension in Mice by Preweaning Food Restriction and by Methionine Restriction in Middle Age.
https://pubmed.ncbi.nlm.nih.gov/19414512/
Low methionine ingestion by rats extends life span.
https://pubmed.ncbi.nlm.nih.gov/8429371/
Fasting glucose level and all-cause or cause-specific mortality in Korean adults: a nationwide cohort study.
Earlier this month, we brought you the news that epigenetic reprogramming startup YouthBio Therapeutics had emerged from stealth. The company shed some light on its plans to develop epigenetic reprogramming therapies for age-related diseases by rejuvenating certain cells in our bodies. YouthBio aims to achieve this rejuvenation by developing gene therapies that enable partial cellular reprogramming – an area of longevity science that is now attracting significant commercial interest.
Longevity. Technology: Cellular reprogramming refers to the process of returning adult cells to a “pluripotent” state: blank, embryonic-like cells that can become any cell in the body. This reprogramming can be achieved using techniques based on the discovery of Yamanaka factors.
Scientists led by Dr. Manuel Serrano have observed symptoms of rejuvenation in the pancreas, liver, spleen, and blood of mice after applying one cycle of cell reprogramming.
To achieve this, the researchers have characterized rejuvenation by studying molecular marks in the DNA, gene expression, and cell metabolism. The study has been published in the journal Aging Cell.
Many diseases, including cancer, are associated with ageing and they are becoming more prevalent as life expectancy increases. Therefore, studying and understanding these processes is crucial if we are to deal with these conditions and also promote healthier aging.
With an aging global population, time is of the essence to find novel targets and therapies for age-related diseases.
A research team from Osaka University in Japan has concluded that a clinical trial of transplanted IPS cell-derived corneal tissue was safe and effective – further evidence that cellular reprogramming with Yamanaka factors is moving towards scalable therapies.
Longevity. Technology: The clinical trial spanned several years and used corneal tissues derived from induced pluripotent stem cells. The tissue was transplanted into four almost-blind patients, and, according to the research team, none of the patients experienced rejection or tumorigenicity of the transplanted cells and all saw improvements in their symptoms, with three experiencing improved eyesight, with one improving from 0.15 to 0.7. Importantly, all were free of side effects one year later.
IPS cells can be generated from any adult cell, with Yamanaka factors – a group of protein transcription factors from four master genes. These induced stem cells demonstrate the significant quality of pluripotency – they can differentiate into all other cell types of the body. This is incredibly useful both for research and for therapy.
Sun, Sep 11 at 12 PM CDT.
This is an invitation to the Annual General Meeting of the Cryonics Institute & the Immortalist Society.
The Cryonics Institute’s Annual General Meeting (AGM) will be held on Sunday, September 11th 2022 from 3:00pm to 6:30pm at the Infinity Hall & Sidebar 16,650 E. 14 Mile Rd, Fraser, MI 48,026 (USA). For more information visit www.infinityhallsidebar.com
Or call (586) 879‑6157.
This is not the first successful research on de-ageing cells. Earlier, Shinya Yamanaka, a Nobel prize-winning stem cell researcher, genetically reprogrammed the mouse skin cells and turned them into induced pluripotent stem cells, or iPSCs, back in 2006. These cells type had the potential to form any cell type in the body. Yamanaka’s method took 50 days and completely reprograms cells to the biological age of an embryo. Gill’s method only took 13 days.
In a statement, Gill said, “Our results represent a big step forward in our understanding of cell reprogramming. We have proved that cells can be rejuvenated without losing their function and that rejuvenation looks to restore some function to old cells.”
This is a 10-minute version with my picks on an hour-and-a-half interview on the longevity science made by Rhonda Patrick to Morgan Levine.
The link to the entire interview, which took place on April 12, 2022, is in the description of the video.
The interview took place on April 2022.
Making positive impacts on human longevity — sonia arrison, author, analyst, investor, entrepreneur.
Sonia Arrison (https://soniaarrison.com/) is a best-selling author, analyst, entrepreneur, and investor.
Sonia is founder of 100 Plus Capital (https://100pluscap.com/ — Investing in companies positively impacting human longevity), Chair of the Alliance for Longevity Initiatives (https://a4li.org/ — The first and only 501©(4) nonprofit organization founded with the goal of creating social and political action around the issues of combating age-related chronic conditions and increasing our number of healthy, disease-free years), co-founder of Unsugarcoat Media (acquired by Medium), and was an associate founder of Singularity University.
She gives a great analogy of slowing aging versus reversing aging, and I did not realize Yamanaka Factors were not so perfect in current use.
In this video Eleanor talks about the her view on Longevity Escape Velocity and reprogramming with Yamanaka factors and some of the issues around this technology.
Eleanor Sheekey graduated from Cambridge University with a masters degree in Biochemistry and is now studying for her PhD at the Cancer Research UK — Cambridge Institute. Eleanor is the person behind the Sheekey Science Show, a popular YouTube channel where she covers longevity and other topics with her deep knowledge of biochemistry.
